In the retinopathy model, the initial prevalence of no retinopathy was 100%. The transition rates were:
0.073, 0.12, and 0.113 (three estimates for the three age cohorts) from state 1 to state 2;
0.0025, 0.00925, and 0.026 from state 2 to state 3;
0.047, 0.0935, and 0.08 from state 2 to state 3;
0.088 (single estimate for all age classes) from state 3 to state 4; and
0.05 from state 4 to state 5.
In the nephropathy model, the initial prevalence of no nephropathy was 100%. The transition rates were:
0.0364, 0.0358, 0.0425, and 0.0419 (four rates apply to periods 1, 2, 3, and 4+ years after transplant) from state 1 to state 2;
0.0246, 0.0242, 0.0286 and 0.0283 from state 1 to state 3;
0.0479, 0.0275, 0.0165, and 0.00468 from state 1 to state 4;
0.09 and 0.099 (two rates apply to periods 1 and 2+ years after transplant) from state 2 to state 1;
0.17 and 0.09 from state 2 to state 4;
0.11 and 0.101 from state 3 to state 1; and
0.09 and 0.0769 from state 3 to state 4.
In the CHD model, the initial prevalence of no CHD was 100% at age 15 years and 77.33% at 35 and 55 years. The initial prevalence of state 2 was 22.67% at 35 and 55 years. The transition rates depended on the patients' characteristics.
In the CVD model, the initial prevalence of no CVD was 100% at age 15 years and 83% at 35 and 55 years. The initial prevalence of state 2 was 17% at 35 and 55 years. The transition rates depended on the patients' characteristics.
In the neuropathy model, the initial prevalence of no PVD was 100% at age 15 years and 96.5% at 35 and 55 years. The initial prevalence of state 2 was 3.5% at 35 and 55 years. The transition rates were:
0.0144 (single rate applies to all periods after transplant) from state 1 to state 2;
0.028, 0.03337, and 0.0467 (three estimates for the three age cohorts) from state 2 to state 3; and
0.1386 from state 3 to state 4.